What Are the Uses of Bimatoprost Ophthalmic Solution?
Bimatoprost, molecular formula is C25H37NO4, molecular weight is 415.5656
Bimatoprost
- Chinese name
- Bimatoprost
- Foreign name
- Bimatoprost
- Molecular weight
- 415.5656
- Molecular formula
- C25H37NO4
- English name
- Bimatoprost
- Relative density
- 1.145g / cm3
- Value
- The strongest resistance to IOP
- Bimatoprost, molecular formula is C25H37NO4, molecular weight is 415.5656
- Chinese alias: (Z) -7-[(1R, 2R, 3R, 5S) -3,5-dihydroxy-2-[(E, 3S) -3-hydroxy-5-phenylpent-1-enyl ] Cyclopentyl] -N-ethylhept-5-enamide
- English alias: N-ETHYL-9ALPHA, 11ALPHA, 15S-TRIHYDROXY-17-PHENYL-18, 19, 20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDE; LUMIGAN; BIMATOPROST (TM); 17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE; BIMATOPROST (LUMIGAN); 17-phenyl-tri-norprostaglandin f2-ethyl amide; (Z) -7-[(1R, 2R, 3R, 5S) -3,5-Dihydroxy-2-[(E , 3S) -3-hydroxy-5-phenylpent-1-enyl] cyclopentyl] -N-ethylhept-5-enamide; (5Z) -7-{(1R, 2R, 3R, 5S) -3,5-dihydroxy- 2-[(1E, 3S) -3-hydroxy-5-phenylpent-1-en-1-yl] cyclopentyl} -N-ethylhept-5-enamide; (5E) -7-{(1R, 2R, 3R, 5S) -3,5-dihydroxy-2-[(1E, 3S) -3-hydroxy-5-phenylpent-1-en-1-yl] cyclopentyl} -N-ethylhept-5-enamide
- CAS: 155206-00-1
- EINECS:-
- Relative density: 1.145g / cm3
- Bimatoprost is considered to be the strongest local anti-IOP effect
- Bimatoprost by adding trabecular meshwork channels and
- 15 healthy subjects were given 0.03% bimatoprost ophthalmic solution one drop at a time, qd, Cmax reached 10 minutes, and the blood concentration of most subjects was below the detection limit (0.025 ng · mL-1) at 1.5 hours. ), D7 and d14 showed no difference in Cmax and AUC0-24h, showing a steady state and no significant accumulation within 1 week after administration. The apparent distribution volume of the drug was 0.67 L · kg-1. Bimatoprost is metabolized to inactive products by oxidation, N-deethylation, and glucuronidation. About 67% is excreted by the kidney and 25% is excreted by feces.
- According to a multi-national research team, bimatoprost is the best choice for glaucoma patients in Europe as a single drug. Bimatoprost (I) is more effective than latanoprost (). Effective and less expensive.
- The researchers used a cost-effect model to evaluate the costs and outcomes of glaucoma treated with 0.03% (I) and 0.005% () eye drops once a day. The study lasted 6 months. The candidates were from Austria and Finland. And France. The model showed that the group (I) achieved the 10P (intraocular pressure) target of 17 mmHg established by the European Glaucoma Association compared with the group (II) (63.8% vs 45.6%).
- In addition, bimatoprost (I) has a better cost-effectiveness ratio than latanoprost in these countries. The cost of IOP compliance per patient is 391 to 827 euros and 514 to 1162 euros. The researchers commented that the main factor contributing to the increase in costs was the number of patients requiring combination therapy. The researchers also pointed out that a 12-month prospective analysis showed that "similar cost-effective ratios are conducive to application (I)." In addition, sensitivity analysis confirmed the stability of the model, with a target value of 13 to 20 mmHg for 10P, bimatoprost (I) had the best potency ratio.